...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Cancer >Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
【24h】

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study

机译：聚乙二醇共轭粒细胞菌落刺激因子（PEG-G-CSF）对叶片治疗的转移结直肠癌患者严重中性粒细胞凋亡的临床效用：单中心回顾性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND:This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice.METHODS:We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3 or 4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0.RESULTS:A total of 26 patients (median age 53.5?years) were included. The ORR rate was 65.3%, the median PFS was 9.6?months (7.2-16.9), and the median OS was 24.2?months (13.6-NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n?=?9) and after the development of grade 3 or 4 neutropenia (n?=?11). No patients experienced grade 3 or 4 neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required.CONCLUSIONS:PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.
机译：背景：本研究旨在评估聚乙二醇共轭粒细胞菌落刺激因子（PEG-G-CSF）预防氟尿嘧啶，白草素，奥沙利铂和Irinotecan（PCRC）患者中的中性粒细胞率患者的疗效和安全性Folfoxiri）在临床实践中加上Bevacizumab（BEV）。方法：我们回顾性分析了2015年12月和2017年12月期间接受了Folfoxiri加BEV的MCRC患者。我们评估了PEG-G-CSF作为预防或治疗3级或4级中性粒细胞病的疗效。根据实体肿瘤的响应评估标准的整体响应率（ORR）根据常见事件版本的常见术语标准，无进展的存活率（PFS），整体存活（PFS），整体存活（OS），以及Folfoxiri Plus BEV的不良事件4.0.Results：共有26名患者（中位数53.5岁？年）。 orr率为65.3％，中位数PFS为9.6？月（7.2-16.9），中位数为24.2？月（13.6纳）。 3级或4级中性粒细胞病发生在53.8％的患者中，发热中性粒细胞贫症发生在7.7％。 PEG-G-CSF给予77.0％的患者，包括预防性（n？=α9）和3级或4级中性粒细胞率（n？= 11）。在施用PEG-G-CSF后，没有患者经历3级或4级中性粒细胞率。在预防PEG-G-CSF的九名患者中的七个患者中，不需要剂量调节。结论：PEG-G-CSF可用于预防MCRC患者的严重中性粒细胞减少症，治疗Folfoxiri Plus BEV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号